EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants

Gabriel Lemieux iD, Jimena Pérez-Vargas, Antoine Désilets iD, Malihe Hassanzadeh, Connor A H Thompson, Alice Gravel-Trudeau, Alexandre Joushomme, Siobhan Ennis, Ivan Villanueva, Étienne Marouseau, Bryan J Fraser iD, William Champagne und 6 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Gabriel Lemieux und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sh…. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Protease Inhibitors, COVID-19 Drug Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Government of Canada, CoVaRR-Net Rapid Response Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The worldwide spread of new SARS-CoV-2 variants emphasizes the need to diversify existing therapeutic strategies. TMPRSS2, a host protease crucial for SARS-CoV-2 entry, has garnered significant research attention as a potential target for therapeutic intervention. Here, we optimized N-0385, a previously reported TMPRSS2 ketobenzothiazole-based peptidomimetic inhibitor, by screening 135 derivatives for target affinity and antiviral potency. Among the top candidates, N-0695 exhibited low nanomolar Ki values against three TTSPs associated with respiratory virus entry: TMPRSS2, matriptase, and TMPRSS13. Notably, N-0920 demonstrated exceptional potency in reducing SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, representing the first in cellulo picomolar inhibitor with EC50 values of 300 and 90 pM, respectively. Additionally, molecular modeling provided insights into the binding interactions between the compounds and their targets. This study underscores the effectiveness of our screening approach in refining an existing peptidomimetic scaffold to enhance selectivity and antiviral activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsProtease InhibitorsCOVID-19 Drug TreatmentHumansSerine EndopeptidasesVirus InternalizationStructure-Activity RelationshipMolecular Docking SimulationCOVID-19SulfonamidesBenzothiazoles

Substanzen

Antiviral AgentsSerine EndopeptidasesTMPRSS2 protein, humanProtease Inhibitors(2S)-N-((2S)-1-(((2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropa…SulfonamidesBenzothiazoles

Autor:innen und Institutionen

  • Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke J1H5N4, Quebec, Canada.
  • Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver V6T 1Z3, British Columbia, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Burnaby J1H5N4, British Columbia, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto M5S 1A1, Ontario, Canada.
  • Structural Genomics Consortium, University of Toronto, Toronto M5S 1A1, Ontario, Canada.
  • Princess Margaret Cancer Centre, Toronto M5S 1A1, Ontario, Canada.

ORCID-Profile: Gabriel Lemieux, Antoine Désilets, Bryan J Fraser, Cheryl H Arrowsmith, François Jean, Pierre-Luc Boudreault

Förderung

  • Government of Canada
  • CoVaRR-Net Rapid Response Research Grant

Zitieren

APA

Lemieux, G., Pérez-Vargas, J., Désilets, A., Hassanzadeh, M., Thompson, C. A. H., Gravel-Trudeau, A., Joushomme, A., Ennis, S., Villanueva, I., Marouseau, É., Fraser, B. J., Champagne, W., Lepage, M., Niikura, M., Arrowsmith, C. H., Jean, F., Leduc, R., & Boudreault, P. L. (2025). From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02468

Vancouver

Lemieux G, Pérez-Vargas J, Désilets A, Hassanzadeh M, Thompson CAH, Gravel-Trudeau A, et al. From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02468

BibTeX
@article{Lemieux2025,
  author = {Lemieux, Gabriel and Pérez-Vargas, Jimena and Désilets, Antoine and Hassanzadeh, Malihe and Thompson, Connor A H and Gravel-Trudeau, Alice and Joushomme, Alexandre and Ennis, Siobhan and Villanueva, Ivan and Marouseau, Étienne and Fraser, Bryan J and Champagne, William and Lepage, Matthieu and Niikura, Masahiro and Arrowsmith, Cheryl H and Jean, François and Leduc, Richard and Boudreault, Pierre-Luc},
  title = {From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02468}
}
Kostenlos starten →